|
|
Line 84: |
Line 84: |
| </div> | | </div> |
| </a> | | </a> |
| + | |
| + | <a href="#duplicate" data-scroll-to data-scroll-to-offset="50" class="list-group-item list-group-item-action d-flex justify-content-between"> |
| + | <div> |
| + | <span>Remove Duplicate Reads - Picard</span> |
| + | </div> |
| + | <div> |
| + | <i class="fas fa-angle-right"></i> |
| + | </div> |
| + | </a> |
| + | |
| + | <a href="#QualityAssessment" data-scroll-to data-scroll-to-offset="50" class="list-group-item list-group-item-action d-flex justify-content-between"> |
| + | <div> |
| + | <span>Base Quality Assessment - GATK</span> |
| + | </div> |
| + | <div> |
| + | <i class="fas fa-angle-right"></i> |
| + | </div> |
| + | </a> |
| + | |
| + | <a href="#MutationCalling" data-scroll-to data-scroll-to-offset="50" class="list-group-item list-group-item-action d-flex justify-content-between"> |
| + | <div> |
| + | <span>Mutation Calling - Mutect2</span> |
| + | </div> |
| + | <div> |
| + | <i class="fas fa-angle-right"></i> |
| + | </div> |
| + | </a> |
| + | |
| + | <a href="#FilterMutations" data-scroll-to data-scroll-to-offset="50" class="list-group-item list-group-item-action d-flex justify-content-between"> |
| + | <div> |
| + | <span>Filter Mutations - GATK</span> |
| + | </div> |
| + | <div> |
| + | <i class="fas fa-angle-right"></i> |
| + | </div> |
| + | </a> |
| + | |
| + | <a href="#GenBasedAnnot" data-scroll-to data-scroll-to-offset="50" class="list-group-item list-group-item-action d-flex justify-content-between"> |
| + | <div> |
| + | <span>Gene-Based Annotation - Annovar</span> |
| + | </div> |
| + | <div> |
| + | <i class="fas fa-angle-right"></i> |
| + | </div> |
| + | </a> |
| + | |
| + | <a href="#SortAnnotProt" data-scroll-to data-scroll-to-offset="50" class="list-group-item list-group-item-action d-flex justify-content-between"> |
| + | <div> |
| + | <span>Sort Annotated Proteins - neoExtract</span> |
| + | </div> |
| + | <div> |
| + | <i class="fas fa-angle-right"></i> |
| + | </div> |
| + | </a> |
| + | |
| + | <a href="#MHCIbind" data-scroll-to data-scroll-to-offset="50" class="list-group-item list-group-item-action d-flex justify-content-between"> |
| + | <div> |
| + | <span>MHC-I-Peptide binding Affinity - NetMHC</span> |
| + | </div> |
| + | <div> |
| + | <i class="fas fa-angle-right"></i> |
| + | </div> |
| + | </a> |
| + | |
| + | <a href="#RankBindAff" data-scroll-to data-scroll-to-offset="50" class="list-group-item list-group-item-action d-flex justify-content-between"> |
| + | <div> |
| + | <span>Rank Binding Affinity - neoSearch </span> |
| + | </div> |
| + | <div> |
| + | <i class="fas fa-angle-right"></i> |
| + | </div> |
| + | </a> |
| + | |
| + | |
| + | |
| + | |
| | | |
| </div> | | </div> |
Line 216: |
Line 292: |
| </p> | | </p> |
| | | |
− | <h1>Quality Assessment - FastQC Analysis</h1> | + | <h1 id="assessment">Quality Assessment - FastQC Analysis</h1> |
| <p class="lead">The data was pre-analysed using FastQC (Version 0.11.7). The program outputs a summary of different metrics of the reads and signals with a flag the scores that are suboptimal for genomic analysis. In general the results show good quality | | <p class="lead">The data was pre-analysed using FastQC (Version 0.11.7). The program outputs a summary of different metrics of the reads and signals with a flag the scores that are suboptimal for genomic analysis. In general the results show good quality |
| of the reads, with overall good per base sequence quality and Per tile sequence quality for all the patient’s data. Furthermore, the per sequence quality score follows the typical trend for good illumina sequence data as seen in Figure | | of the reads, with overall good per base sequence quality and Per tile sequence quality for all the patient’s data. Furthermore, the per sequence quality score follows the typical trend for good illumina sequence data as seen in Figure |
Line 394: |
Line 470: |
| <br> | | <br> |
| | | |
− | <h1>Remove Duplicate Reads - Picard</h1> | + | <h1 id="duplicate">Remove Duplicate Reads - Picard</h1> |
| <p class="lead">After assessing the quality of the samples with FastQC, the reports show that more than 20% of the total sample is composed by duplicated and non-unique sequences as seen in Figure 3 (Shlee). The duplicated sequences were search and deleted | | <p class="lead">After assessing the quality of the samples with FastQC, the reports show that more than 20% of the total sample is composed by duplicated and non-unique sequences as seen in Figure 3 (Shlee). The duplicated sequences were search and deleted |
| from the libraries using Picard Tools (v 2.18.14) MarkDuplicates program. The remove sequencing duplicates option was tagged to output the file with the duplicated sequences already removed. Alternatively, it is possible to flag the | | from the libraries using Picard Tools (v 2.18.14) MarkDuplicates program. The remove sequencing duplicates option was tagged to output the file with the duplicated sequences already removed. Alternatively, it is possible to flag the |
Line 453: |
Line 529: |
| </table> | | </table> |
| | | |
− | <h1>Base quality assessment - GATK</h1> | + | <h1 id="QualityAssessment">Base quality assessment - GATK</h1> |
| <p class="lead">Variant calling algorithms are heavily sensitive to the quality scores of the sequences. The base quality scores are often subjected to various technical errors due to the sequencing technique. For this reason base recalibration is key | | <p class="lead">Variant calling algorithms are heavily sensitive to the quality scores of the sequences. The base quality scores are often subjected to various technical errors due to the sequencing technique. For this reason base recalibration is key |
| to ensure that the quality scores are accurate and that the variant calling analysis is accurate. Base recalibration was perform with BaseRecalibrator inside GATK package (v 4.0.9.0) (McKenna et al. 1297-1303). </p> | | to ensure that the quality scores are accurate and that the variant calling analysis is accurate. Base recalibration was perform with BaseRecalibrator inside GATK package (v 4.0.9.0) (McKenna et al. 1297-1303). </p> |
Line 544: |
Line 620: |
| <br> | | <br> |
| | | |
− | <h1>Mutation Calling - Mutect2</h1> | + | <h1 id="MutationCalling">Mutation Calling - Mutect2</h1> |
| <p class="lead">Mutation calling is one of the core functions of the Ginga pipeline. The somatic mutations found in the samples are responsible for the modifications in the final translated proteins and effectively the neoantigen sequences that Ginga | | <p class="lead">Mutation calling is one of the core functions of the Ginga pipeline. The somatic mutations found in the samples are responsible for the modifications in the final translated proteins and effectively the neoantigen sequences that Ginga |
| aims to detect. Unfortunately, due to the lack of ethical approval to access other patient’s dataset and the concerns regarding the data protection of whole exome sequences, the results of this validation were perform without a reference | | aims to detect. Unfortunately, due to the lack of ethical approval to access other patient’s dataset and the concerns regarding the data protection of whole exome sequences, the results of this validation were perform without a reference |
Line 583: |
Line 659: |
| <br> | | <br> |
| | | |
− | <h1>Filter Mutations - GATK</h1> | + | <h1 id="FilterMutations">Filter Mutations - GATK</h1> |
| <p class="lead">Due to the lack of matched normal to perform the mutation calling analysis, there is a higher risk to select false positives in the pipeline. Some of these artifacts are generated by the presence of cross-sample contamination in the original | | <p class="lead">Due to the lack of matched normal to perform the mutation calling analysis, there is a higher risk to select false positives in the pipeline. Some of these artifacts are generated by the presence of cross-sample contamination in the original |
| FASTQ file and are due to sequencing technique. For this reason, it is important to reduce the large pool of mutations generated and filter them accordingly. This can be done by using GetPileupSummaries, CalculateContamination and FilterMutectCalls | | FASTQ file and are due to sequencing technique. For this reason, it is important to reduce the large pool of mutations generated and filter them accordingly. This can be done by using GetPileupSummaries, CalculateContamination and FilterMutectCalls |
Line 597: |
Line 673: |
| field contains the reads that are supported by the germline resource. | | field contains the reads that are supported by the germline resource. |
| </p> | | </p> |
| + | <br> |
| + | <p class="lead">The pileup summaries table was then used to calculate the fraction of cross-sample contamination in the tumor reads and output the contamination table that can be used to filter the mutations. The resulting table contains the estimates |
| + | for contamination and error in the sample. Furthermore, CalculateContamination also supports an alternate mode which uses the matched normal sample to improve on the accuracy of the analysis.The results show that the contamination levels |
| + | for the samples are relatively low. |
| + | </p> |
| + | <br> |
| + | <p class="lead">Table 8 - Contamination Table for sample ERR2683866.</p> |
| + | <table> |
| + | <tr> |
| + | <th>Sample</th> |
| + | <th>Contamination</th> |
| + | <th>Error</th> |
| + | </tr> |
| + | <tr> |
| + | <td>ERR2683866</td> |
| + | <td>0.004125546</td> |
| + | <td>0.001190943</td> |
| + | </tr> |
| + | </table> |
| | | |
| + | <br> |
| | | |
− | </div>
| + | <p class="lead">The mutations outputted by Mutect2 were filtered using FilterMutectCalls. This applies a preset of thresholds and filters to remove false positives from the data. It uses the contamination table as an additional input. FilterMutectCalls |
| + | outputs a VCF and index file, containing the true positives with the PASS label and the false positives with the FILTER field. </p> |
| | | |
− | <div class="tab-pane fade" id="Vaccine" role="tabpanel" aria-labelledby="profile-tab">
| + | <h1 id="GenBasedAnnot">Gene-Based Annotation - Annovar</h1> |
| + | <p class="lead">The gene-based annotation was performed using Annovar (v. 2018Apr16) annotate_variation.pl script. Gene-based annotation was used to annotate the mutations of the discover in the samples and the coding_change.pl was change to translate |
| + | the annotated sequences into the corresponding coding proteins. Additionally, filter-based mutation was used to filter mutations from the Cosmic Database and the International Cancer Genome Consortium (ICGC) database. |
| + | </p> |
| <br> | | <br> |
| + | <p class="lead">Annovar uses the predetermined file format VCF4 for the inputs. The annotated mutations from Mutect2 or other GATK packages commonly found in VCF format can be converted using the perl code convert2annovar.pl. This tool adds three additional |
| + | rows to the VCF format, zygosity status, genotype quality and read depth. The genotype calling files from the samples extracted after filtering the contamination with FilterMutectCalls were converted to VCF4 format. |
| + | </p> |
| + | <br> |
| + | <p class="lead">Before annotating the samples with annovar, the FASTA sequences for all annotated transcripts in RefSeq Gene hg19, were downloaded using the built-in --downdb argument in the annotated_variation.pl package. This argument allows you to |
| + | access files directly from the UCSC Genome Browser Annotation Database. Furthermore, the reference gRNA files were created using the retrieve_seq_from_fasta.pl package in Annovar. The VCF4 were annotated using the core function of Annovar, |
| + | the annotate_variation.pl program. Standard parameters were selected and the hg19 refGene was used as a reference. The annotated variations are outputted in two different VCF files. The variant_function VCF file, contains the information |
| + | regarding the nature of the variation and the position in the exome. This file summarises if the variant is exonic, splicing, or if it hit a non-coding RNA genes, as well as the gene containing the mutation. The second file, exonic_variant_function |
| + | VCF file, contains the amino acid changes as a result of the exonic variant and furthermore identifies the type of functional consequences caused by the variant (frameshift insertion, deletion,frameshift block substitution...). The exonic_variant_function |
| + | VCF annotations, were translated into protein sequences through the coding_change.pl tool in Annovar. This outputs a FASTA format containing the wild type and mutated protein sequences under a header containing the original mutation, |
| + | gene affected and amino acid sequence change. All the annotation results can be found in Ginga’s Github. |
| + | </p> |
| | | |
− | <div class="row justify-content-center lead"> | + | <h1 id="SortAnnotProt">Sort Annotated Proteins - neoExtract</h1> |
| | | |
− | <div class="col-lg-3">
| + | <p class="lead">The proteins annotated in Annovar contain both the mutated sequence as well as the wild type protein. Moreover, since neoantigen sequences are typically 8 to 11 amino acids long, the major part of protein sequence which doesn’t contain |
− | <div class="card">
| + | any functional variation associated with the cancer mutation of the sample, has no implications on the end library of neoantigens. For determining the final neoantigens, only a short amino acid sequence around the mutation is required, |
− | <div class="card-header">
| + | in the case of SNVs. neoExtract was used to sort the annotated proteins, removing the wildtype from the Annovar FA output file, and only retains a short amino acid sequence of specified length around the mutation. The coding change exonic |
− | <span class="h5">Index</span>
| + | variant function, was processed by neoExtract, using standard parameters. The output FASTA file contains all the possible combinations of neoantigen candidates derived from the mutated proteins. neoExtract can also process other functional |
− | </div>
| + | consequences of the variant such as insertions, deletions and frameshift. The first 10 results from the |
− | <div class="list-group list-group-flush">
| + | </p> |
| | | |
− | <a href="#Achievements" data-scroll-to data-scroll-to-offset="50" class="list-group-item list-group-item-action d-flex justify-content-between">
| + | <br> |
− | <div>
| + | |
− | <span>Achievements</span>
| + | |
− | </div>
| + | |
− | <div>
| + | |
− | <i class="fas fa-angle-right"></i>
| + | |
− | </div>
| + | |
− | </a>
| + | |
− | <a href="#cellfree" data-scroll-to data-scroll-to-offset="50" class="list-group-item list-group-item-action d-flex justify-content-between">
| + | |
− | <div>
| + | |
− | <span>CellFree</span>
| + | |
− | </div>
| + | |
− | <div>
| + | |
− | <i class="fas fa-angle-right"></i>
| + | |
− | </div>
| + | |
− | </a>
| + | |
− | <a href="#plasmidConstruction" data-scroll-to data-scroll-to-offset="50" class="list-group-item list-group-item-action d-flex justify-content-between">
| + | |
− | <div>
| + | |
− | <span>Plasmid Construction</span>
| + | |
− | </div>
| + | |
− | <div>
| + | |
− | <i class="fas fa-angle-right"></i>
| + | |
− | </div>
| + | |
− | </a>
| + | |
− | <a href="#HHE" data-scroll-to data-scroll-to-offset="50" class="list-group-item list-group-item-action d-flex justify-content-between">
| + | |
− | <div>
| + | |
− | <span>HexaHistidine Encapsulin cell-free expression and purification</span>
| + | |
− | </div>
| + | |
− | <div>
| + | |
− | <i class="fas fa-angle-right"></i>
| + | |
− | </div>
| + | |
− | </a>
| + | |
| | | |
− | <a href="#PlasmidConstruction2" data-scroll-to data-scroll-to-offset="50" class="list-group-item list-group-item-action d-flex justify-content-between">
| + | <h1 id="MHCIbind">MHC-I-Peptide binding Affinity - NetMHC</h1> |
− | <div>
| + | <p class="lead">In order to determine if the neontaingen candidates can be presented in the surface of of antigen presenting cells such as dendritic cells, which are the precursors of the immune response, the neoantigens need to have a high binding affinity |
− | <span>Plasmid construction (HexaHistidine Encapsulin with C-terminus BsaI cut sites)</span>
| + | to the MHC-I complexes on the cell surface. This MHC-I complexes are specific for cytotoxic cytokine releasing CD8+ T cells, that can target and lysate the tumor cells. In order to shortlist the best neoantigen candidates, the neoantigens |
− | </div>
| + | etracted can be rank according to their binding affinity to MHC-I complexes. This was performed using netMHC (v 4.0)(Andreatta and Nielsen 511-517). The FASTA file containing the candidate neoantigens was input and 8 to 14mer peptide |
− | <div>
| + | len gth was selected to obtain the widest library of neoantigens. The species/loci chosen was the standear HLA supertype representative. To test the system only alleles of class HLA-A were selected, including HLA-A0101, HLA-A0201, HLA-A0301, |
− | <i class="fas fa-angle-right"></i>
| + | HLA-A2402, HLA-A2601. The options to sort by predicted affinity and save output in XLS format, were also selected in order to be able to easily postprocess the neoantigens. The results of the analysis can be found in the Ginga Github. |
− | </div>
| + | </p> |
− | </a>
| + | <br> |
| + | <p class="lead">Additionally, to netMHC Ginga also includes the support to mixMHCpred, a software that adds mass-spectrometry analysis of the MHC-I alleles to improve the prediction of MHC-I-peptide binding (Bassani-Sternberg M et al.). However, this |
| + | is currently under development. |
| + | </p> |
| | | |
− | <a href="#incorporation" data-scroll-to data-scroll-to-offset="50" class="list-group-item list-group-item-action d-flex justify-content-between">
| + | <br> |
− | <div>
| + | |
− | <span>Incorporation of the OT1 coding sequence into our platform</span>
| + | |
− | </div>
| + | |
− | <div>
| + | |
− | <i class="fas fa-angle-right"></i>
| + | |
− | </div>
| + | |
− | </a>
| + | |
| | | |
− | <a href="#EncapOT1" data-scroll-to data-scroll-to-offset="50" class="list-group-item list-group-item-action d-flex justify-content-between">
| + | <h1 id="RankBindAff">Rank Binding Affinity - neoSearch </h1> |
− | <div>
| + | <p class="lead">Although, netMHC can sort the peptide sequences by their ranking affinity this data is difficult to organis. Furthermore, sorting the peptides according to their binding affinity and not the parent sequence that they originate from is |
− | <span>Encapsulin-OT1 cell-free expression and purification</span>
| + | currently not possible. neoSearch sorts the XLS file from netMHC and returns the ranked neoantigens in a CSV file that can be easily read and processed to create high throughput therapeutics. The final expected results of the pipeline |
− | </div>
| + | can be found in the Ginga Github and a brief summary of the results can be found in Table 9. |
− | <div>
| + | </p> |
− | <i class="fas fa-angle-right"></i>
| + | <br> |
− | </div>
| + | <p class="lead">neoSearch has also the option to obtain the original exome mutated sequence and index position, of the mutation that coded the specific neoantigen. neoSearch uses the protein index and the VCF file outputted by Mutect2 to find the original |
− | </a>
| + | coding sequence for the neoantigen candidate. The length of the sequence extracted can be adjusted accordingly, to detect the . The purpose of this trace back is to |
| + | </p> |
| + | <br> |
| + | <p class="lead">Table 9 - First 19 neoantigens discovered for sample ERR2683866 for the HLA-A0101 allele. The SB label indicates the binding affinity (SB). |
| + | </p> |
| + | <br> |
| + | <table> |
| + | <tr> |
| + | <th>HLA-A0101</th> |
| + | <th></th> |
| + | <th>Sample ERR2683866</th> |
| + | <th></th> |
| + | <th></th> |
| + | <th></th> |
| + | <th></th> |
| + | </tr> |
| + | <tr> |
| + | <td>Pos</td> |
| + | <td>Peptide</td> |
| + | <td>ID</td> |
| + | <td>nM</td> |
| + | <td>Rank</td> |
| + | <td>Core</td> |
| + | <td></td> |
| + | </tr> |
| + | <tr> |
| + | <td>18</td> |
| + | <td>PTNTYTLDY</td> |
| + | <td>line216_NM_0013</td> |
| + | <td>5.2</td> |
| + | <td>0.01</td> |
| + | <td>PTNTYTLDY</td> |
| + | <td>SB</td> |
| + | </tr> |
| + | <tr> |
| + | <td>17</td> |
| + | <td>VPTNTYTLDY</td> |
| + | <td>line216_NM_0013</td> |
| + | <td>12.1</td> |
| + | <td>0.02</td> |
| + | <td>VTNTYTLDY</td> |
| + | <td>SB</td> |
| + | </tr> |
| + | <tr> |
| + | <td>15</td> |
| + | <td>TTVPTNTYTLDY</td> |
| + | <td>line216_NM_0013</td> |
| + | <td>25.8</td> |
| + | <td>0.04</td> |
| + | <td>TTNTYTLDY</td> |
| + | <td>SB</td> |
| + | </tr> |
| + | <tr> |
| + | <td>14</td> |
| + | <td>KTTVPTNTYTLDY</td> |
| + | <td>line216_NM_0013</td> |
| + | <td>25.8</td> |
| + | <td>0.04</td> |
| + | <td>TTNTYTLDY</td> |
| + | <td>SB</td> |
| + | </tr> |
| + | <tr> |
| + | <td>13</td> |
| + | <td>EKTTVPTNTYTLDY</td> |
| + | <td>line216_NM_0013</td> |
| + | <td>23.9</td> |
| + | <td>0.04</td> |
| + | <td>TTNTYTLDY</td> |
| + | <td>SB</td> |
| + | </tr> |
| + | <tr> |
| + | <td>6</td> |
| + | <td>HTAGTFLSY</td> |
| + | <td>line16092_NM_00</td> |
| + | <td>24.2</td> |
| + | <td>0.04</td> |
| + | <td>HTAGTFLSY</td> |
| + | <td>SB</td> |
| + | </tr> |
| + | <tr> |
| + | <td>16</td> |
| + | <td>TVPTNTYTLDY</td> |
| + | <td>line216_NM_0013</td> |
| + | <td>27.9</td> |
| + | <td>0.05</td> |
| + | <td>TTNTYTLDY</td> |
| + | <td>SB</td> |
| + | </tr> |
| + | <tr> |
| + | <td>19</td> |
| + | <td>TNTYTLDY</td> |
| + | <td>line216_NM_0013</td> |
| + | <td>57.9</td> |
| + | <td>0.1</td> |
| + | <td>_TNTYTLDY</td> |
| + | <td>SB</td> |
| + | </tr> |
| + | <tr> |
| + | <td>5</td> |
| + | <td>MHTAGTFLSY</td> |
| + | <td>line16092_NM_00</td> |
| + | <td>90.2</td> |
| + | <td>0.15</td> |
| + | <td>MTAGTFLSY</td> |
| + | <td>SB</td> |
| + | </tr> |
| + | <tr> |
| + | <td>18</td> |
| + | <td>ESDSIQWFH</td> |
| + | <td>line10122_NM_00</td> |
| + | <td>241.5</td> |
| + | <td>0.25</td> |
| + | <td>ESDSIQWFH</td> |
| + | <td>SB</td> |
| + | </tr> |
| + | <tr> |
| + | <td>11</td> |
| + | <td>LVTAALVALGVLY</td> |
| + | <td>line284_NM_0334</td> |
| + | <td>345.2</td> |
| + | <td>0.3</td> |
| + | <td>VTAALVALY</td> |
| + | <td>SB</td> |
| + | </tr> |
| + | <tr> |
| + | <td>10</td> |
| + | <td>LLVTAALVALGVLY</td> |
| + | <td>line284_NM_0334</td> |
| + | <td>339.9</td> |
| + | <td>0.3</td> |
| + | <td>VTAALVALY</td> |
| + | <td>SB</td> |
| + | </tr> |
| + | <tr> |
| + | <td>4</td> |
| + | <td>VMHTAGTFLSY</td> |
| + | <td>line16092_NM_00</td> |
| + | <td>340.6</td> |
| + | <td>0.3</td> |
| + | <td>MTAGTFLSY</td> |
| + | <td>SB</td> |
| + | </tr> |
| + | <tr> |
| + | <td>3</td> |
| + | <td>AVMHTAGTFLSY</td> |
| + | <td>line16092_NM_00</td> |
| + | <td>348.9</td> |
| + | <td>0.3</td> |
| + | <td>MTAGTFLSY</td> |
| + | <td>SB</td> |
| + | </tr> |
| + | <tr> |
| + | <td>2</td> |
| + | <td>IAVMHTAGTFLSY</td> |
| + | <td>line16092_NM_00</td> |
| + | <td>342.8</td> |
| + | <td>0.3</td> |
| + | <td>MTAGTFLSY</td> |
| + | <td>SB</td> |
| + | </tr> |
| + | <tr> |
| + | <td>1</td> |
| + | <td>LIAVMHTAGTFLSY</td> |
| + | <td>line16092_NM_00</td> |
| + | <td>289.3</td> |
| + | <td>0.3</td> |
| + | <td>MTAGTFLSY</td> |
| + | <td>SB</td> |
| + | </tr> |
| + | <tr> |
| + | <td>12</td> |
| + | <td>VTAALVALGVLY</td> |
| + | <td>line284_NM_0334</td> |
| + | <td>381.9</td> |
| + | <td>0.4</td> |
| + | <td>VTAALVALY</td> |
| + | <td>SB</td> |
| + | </tr> |
| + | <tr> |
| + | <td>0</td> |
| + | <td>TSEAFSSY</td> |
| + | <td>line4423_NM_021</td> |
| + | <td>446.9</td> |
| + | <td>0.4</td> |
| + | <td>TSEAFSS_Y</td> |
| + | <td>SB</td> |
| + | </tr> |
| + | <tr> |
| + | <td>0</td> |
| + | <td>LSLEDLSQLAV</td> |
| + | <td>line20806_NM_01</td> |
| + | <td>499.6</td> |
| + | <td>0.4</td> |
| + | <td>LSDLSQLAV</td> |
| + | <td>SB</td> |
| + | </tr> |
| + | </table> |
| | | |
− | <a href="#massSpec" data-scroll-to data-scroll-to-offset="50" class="list-group-item list-group-item-action d-flex justify-content-between">
| + | </div> |
− | <div>
| + | |
− | <span>Encapsulin-OT1 mass spec</span>
| + | |
− | </div>
| + | |
− | <div>
| + | |
− | <i class="fas fa-angle-right"></i>
| + | |
− | </div>
| + | |
− | </a>
| + | |
| | | |
− | <a href="#HHEOT1" data-scroll-to data-scroll-to-offset="50" class="list-group-item list-group-item-action d-flex justify-content-between">
| |
− | <div>
| |
− | <span>HexaHistidine Encapsulin-OT1</span>
| |
− | </div>
| |
− | <div>
| |
− | <i class="fas fa-angle-right"></i>
| |
− | </div>
| |
− | </a>
| |
| | | |
− | <a href="#HHEcontrol" data-scroll-to data-scroll-to-offset="50" class="list-group-item list-group-item-action d-flex justify-content-between">
| + | <div class="tab-pane fade" id="Vaccine" role="tabpanel" aria-labelledby="profile-tab"> |
− | <div>
| + | <br> |
− | <span>HexaHistidine Encapsulin (control)</span>
| + | |
− | </div>
| + | |
− | <div>
| + | |
− | <i class="fas fa-angle-right"></i>
| + | |
− | </div>
| + | |
− | </a>
| + | |
| | | |
− | <a href="#Encapuptake" data-scroll-to data-scroll-to-offset="50" class="list-group-item list-group-item-action d-flex justify-content-between">
| + | <div class="row justify-content-center lead"> |
− | <div>
| + | |
− | <span>Encapsulin uptake by dendritic cells</span>
| + | |
− | </div>
| + | |
− | <div>
| + | |
− | <i class="fas fa-angle-right"></i>
| + | |
− | </div>
| + | |
− | </a>
| + | |
| | | |
| + | <div class="col-lg-3"> |
| + | <div class="card"> |
| + | <div class="card-header"> |
| + | <span class="h5">Index</span> |
| + | </div> |
| + | <div class="list-group list-group-flush"> |
| | | |
− | </div>
| + | <a href="#Achievements" data-scroll-to data-scroll-to-offset="50" class="list-group-item list-group-item-action d-flex justify-content-between"> |
− | </div>
| + | <div> |
− | </div>
| + | <span>Achievements</span> |
| + | </div> |
| + | <div> |
| + | <i class="fas fa-angle-right"></i> |
| + | </div> |
| + | </a> |
| + | <a href="#cellfree" data-scroll-to data-scroll-to-offset="50" class="list-group-item list-group-item-action d-flex justify-content-between"> |
| + | <div> |
| + | <span>CellFree</span> |
| + | </div> |
| + | <div> |
| + | <i class="fas fa-angle-right"></i> |
| + | </div> |
| + | </a> |
| + | <a href="#plasmidConstruction" data-scroll-to data-scroll-to-offset="50" class="list-group-item list-group-item-action d-flex justify-content-between"> |
| + | <div> |
| + | <span>Plasmid Construction</span> |
| + | </div> |
| + | <div> |
| + | <i class="fas fa-angle-right"></i> |
| + | </div> |
| + | </a> |
| + | <a href="#HHE" data-scroll-to data-scroll-to-offset="50" class="list-group-item list-group-item-action d-flex justify-content-between"> |
| + | <div> |
| + | <span>HexaHistidine Encapsulin cell-free expression and purification</span> |
| + | </div> |
| + | <div> |
| + | <i class="fas fa-angle-right"></i> |
| + | </div> |
| + | </a> |
| | | |
− | <div class="col-lg-9">
| + | <a href="#PlasmidConstruction2" data-scroll-to data-scroll-to-offset="50" class="list-group-item list-group-item-action d-flex justify-content-between"> |
− | <h1>Encapsulin protein cage nanocarrier - Toward high throughput production of personalized cancer vaccines</h1>
| + | <div> |
| + | <span>Plasmid construction (HexaHistidine Encapsulin with C-terminus BsaI cut sites)</span> |
| + | </div> |
| + | <div> |
| + | <i class="fas fa-angle-right"></i> |
| + | </div> |
| + | </a> |
| | | |
− | <br>
| + | <a href="#incorporation" data-scroll-to data-scroll-to-offset="50" class="list-group-item list-group-item-action d-flex justify-content-between"> |
− | <p class="lead">Encapsulin, a protein cage nanoparticle derived from the bacteria T. maritima, has shown promising potential as effective antigen delivery platform for cancer vaccine immunotherapy. (<a href="https://www.ncbi.nlm.nih.gov/pubmed/27390910"><span style="color:blue">Choi et al., 2016</span></a>).
| + | <div> |
− | For the purposes of having a straightforward purification of our vaccine, we added an HexaHistidine tag between amino acids 43 and 44 of the Encapsulin monomer, forming a loop on each subunit that point to the interior surface of
| + | <span>Incorporation of the OT1 coding sequence into our platform</span> |
− | the multimer. This version of Encapsulin has proven higher heat resistance and stability, as well as better hydrodynamic properties (Moon et al., 2014). Encapsulin is genetically well-characterized and we designed a platform enabling
| + | </div> |
− | easy genetic incorporation of any peptide on its surface following the work done by <a href="https://www.ncbi.nlm.nih.gov/pubmed/27390910"><span style="color:blue">Choi et al., 2016</span></a>. This has been achieved by adding cut
| + | <div> |
− | sites at the C-terminus of the protein coding sequence. The peptide of interest sequence can then be incorporated in the platform using Golden Gate assembly. With a view to cell-free production of our vaccine, the platform was optimized
| + | <i class="fas fa-angle-right"></i> |
− | for E.Coli expression under T7 promoter.
| + | </div> |
− | </p>
| + | </a> |
| | | |
| + | <a href="#EncapOT1" data-scroll-to data-scroll-to-offset="50" class="list-group-item list-group-item-action d-flex justify-content-between"> |
| + | <div> |
| + | <span>Encapsulin-OT1 cell-free expression and purification</span> |
| + | </div> |
| + | <div> |
| + | <i class="fas fa-angle-right"></i> |
| + | </div> |
| + | </a> |
| | | |
| + | <a href="#massSpec" data-scroll-to data-scroll-to-offset="50" class="list-group-item list-group-item-action d-flex justify-content-between"> |
| + | <div> |
| + | <span>Encapsulin-OT1 mass spec</span> |
| + | </div> |
| + | <div> |
| + | <i class="fas fa-angle-right"></i> |
| + | </div> |
| + | </a> |
| | | |
− | </div>
| + | <a href="#HHEOT1" data-scroll-to data-scroll-to-offset="50" class="list-group-item list-group-item-action d-flex justify-content-between"> |
| + | <div> |
| + | <span>HexaHistidine Encapsulin-OT1</span> |
| + | </div> |
| + | <div> |
| + | <i class="fas fa-angle-right"></i> |
| + | </div> |
| + | </a> |
| | | |
− | </div>
| + | <a href="#HHEcontrol" data-scroll-to data-scroll-to-offset="50" class="list-group-item list-group-item-action d-flex justify-content-between"> |
| + | <div> |
| + | <span>HexaHistidine Encapsulin (control)</span> |
| + | </div> |
| + | <div> |
| + | <i class="fas fa-angle-right"></i> |
| + | </div> |
| + | </a> |
| | | |
− | <div class="col-lg-12">
| + | <a href="#Encapuptake" data-scroll-to data-scroll-to-offset="50" class="list-group-item list-group-item-action d-flex justify-content-between"> |
− | <h1 class="text-center" id="Achievements">Achievements</h1>
| + | <div> |
| + | <span>Encapsulin uptake by dendritic cells</span> |
| + | </div> |
| + | <div> |
| + | <i class="fas fa-angle-right"></i> |
| + | </div> |
| + | </a> |
| | | |
| | | |
| + | </div> |
| + | </div> |
| + | </div> |
| | | |
| + | <div class="col-lg-9"> |
| + | <h1>Encapsulin protein cage nanocarrier - Toward high throughput production of personalized cancer vaccines</h1> |
| | | |
− | </div>
| + | <br> |
| + | <p class="lead">Encapsulin, a protein cage nanoparticle derived from the bacteria T. maritima, has shown promising potential as effective antigen delivery platform for cancer vaccine immunotherapy. (<a href="https://www.ncbi.nlm.nih.gov/pubmed/27390910"><span style="color:blue">Choi et al., 2016</span></a>). |
| + | For the purposes of having a straightforward purification of our vaccine, we added an HexaHistidine tag between amino acids 43 and 44 of the Encapsulin monomer, forming a loop on each subunit that point to the interior surface of |
| + | the multimer. This version of Encapsulin has proven higher heat resistance and stability, as well as better hydrodynamic properties (Moon et al., 2014). Encapsulin is genetically well-characterized and we designed a platform enabling |
| + | easy genetic incorporation of any peptide on its surface following the work done by <a href="https://www.ncbi.nlm.nih.gov/pubmed/27390910"><span style="color:blue">Choi et al., 2016</span></a>. This has been achieved by adding cut |
| + | sites at the C-terminus of the protein coding sequence. The peptide of interest sequence can then be incorporated in the platform using Golden Gate assembly. With a view to cell-free production of our vaccine, the platform was optimized |
| + | for E.Coli expression under T7 promoter. |
| + | </p> |
| | | |
− | <div class="col-lg-12">
| |
− | <h1 id="cellfree">Cell-free expression of proteins</h1>
| |
− | <p class="lead">Assessing the efficiency of our TX-TL (Sun et al., 2013) cell-free system is key before expressing our protein of interest. To do so, we made use of the fluorescence of sfGFP to assess the efficiency of expression. We therefore expressed
| |
− | sfGFP in our cell-free system and measured fluorescence with a microplate reader over time, following this protocol (LINK). We used this kind of experiments as an internal reference to assess in a relative way the quality of our lysates
| |
− | and energy solutions.
| |
− | </p>
| |
| | | |
− | <br>
| |
− | <figure>
| |
− | <img src="https://static.igem.org/mediawiki/2018/3/35/T--EPFL--vaccine_result1.png" class="img-center img-fluid rounded shadow" width="800">
| |
− | <figcaption class="mt-3 text-muted">Figure 1: Microplate reader measurement of fluorescence over time. Measurements were taken every 90s during approximately 6h (with a quick shake between each measurement). The samples were hold at 29°C.The positive sample is a cell-free
| |
− | expression of sfGFP template. In the negative control sample, the plasmid stock solution volume was replaced with nuclease free water.</figcaption>
| |
− | </figure>
| |
− | <br>
| |
− | <p class="lead">This is the maximum fluorescence intensity we have gotten, that is, around 200 000 RFU (Relative Fluorescence Units).</p>
| |
− | <br>
| |
| | | |
− | <h1 id="plasmidConstruction">Plasmid construction</h1>
| + | </div> |
| | | |
− | <figure> | + | </div> |
− | <img src="https://static.igem.org/mediawiki/2018/3/38/T--EPFL--vaccine_result2.png" class="img-center img-fluid rounded shadow" width="400">
| + | |
− | <figcaption class="mt-3 text-muted">Figure 2: Schematic overview of our plasmid construct containing HexaHistidine Encapsulin coding sequence </figcaption>
| + | |
− | </figure>
| + | |
| | | |
− | <br> | + | <div class="col-lg-12"> |
| + | <h1 class="text-center" id="Achievements">Achievements</h1> |
| | | |
− | <figure>
| |
− | <img src="https://static.igem.org/mediawiki/2018/f/ff/T--EPFL--vaccine_result3.png" class="img-center img-fluid rounded shadow" width="800">
| |
− | <figcaption class="mt-3 text-muted">Gel electrophoresis of both the HexaHistidine insert (first gel) and the Encapsulin and plasmid backbone (second gel) . The bands at the correct length were extracted and assembled using a Golden Gate assembly.
| |
− | </figcaption>
| |
| | | |
− | </figure>
| |
| | | |
− | <br>
| |
| | | |
− | <figure> | + | </div> |
− | <img src="https://static.igem.org/mediawiki/2018/e/ec/T--EPFL--vaccine_result4.png" class="img-center img-fluid rounded shadow" width="400">
| + | |
− | </figure>
| + | |
| | | |
− | <br> | + | <div class="col-lg-12"> |
| + | <h1 id="cellfree">Cell-free expression of proteins</h1> |
| + | <p class="lead">Assessing the efficiency of our TX-TL (Sun et al., 2013) cell-free system is key before expressing our protein of interest. To do so, we made use of the fluorescence of sfGFP to assess the efficiency of expression. We therefore expressed |
| + | sfGFP in our cell-free system and measured fluorescence with a microplate reader over time, following the <a href="https://2017.igem.org/Team:EPFL/Protocols">2017 EPFL iGEM protocol</a>. We used this kind of experiments as an internal |
| + | reference to assess in a relative way the quality of our lysates and energy solutions. |
| + | </p> |
| | | |
− | <h1 id="HHE">HexaHistidine Encapsulin cell-free expression and purification</h1>
| + | <br> |
− | <br>
| + | <figure> |
| + | <img src="https://static.igem.org/mediawiki/2018/3/35/T--EPFL--vaccine_result1.png" class="img-center img-fluid rounded shadow" width="800"> |
| + | <figcaption class="mt-3 text-muted">Figure 1: Microplate reader measurement of fluorescence over time. Measurements were taken every 90s during approximately 6h (with a quick shake between each measurement). The samples were hold at 29°C.The positive sample is a cell-free |
| + | expression of sfGFP template. In the negative control sample, the plasmid stock solution volume was replaced with nuclease free water.</figcaption> |
| + | </figure> |
| + | <br> |
| + | <p class="lead">This is the maximum fluorescence intensity we have gotten, that is, around 200 000 RFU (Relative Fluorescence Units).</p> |
| + | <br> |
| | | |
− | <p class="lead">In this section, we show some results of our trials to express HexaHistidine Encapsulin in our cell-free systems, as well as heat purify it.</p>
| + | <h1 id="plasmidConstruction">Plasmid construction</h1> |
| | | |
− | <p class="lead">The cell-free expression were done following a standard protocol (LINK): 8 to 12h of expression at 29°C with shaking (600rpm).</p>
| + | <figure> |
| + | <img src="https://static.igem.org/mediawiki/2018/3/38/T--EPFL--vaccine_result2.png" class="img-center img-fluid rounded shadow" width="400"> |
| + | <figcaption class="mt-3 text-muted">Figure 2: Schematic overview of our plasmid construct containing HexaHistidine Encapsulin coding sequence </figcaption> |
| + | </figure> |
| | | |
− | <br>
| + | <br> |
| | | |
− | <figure>
| + | <figure> |
− | <img src="https://static.igem.org/mediawiki/2018/3/3f/T--EPFL--vaccine_result5.png" class="img-center img-fluid rounded shadow" width="800">
| + | <img src="https://static.igem.org/mediawiki/2018/f/ff/T--EPFL--vaccine_result3.png" class="img-center img-fluid rounded shadow" width="800"> |
− | <figcaption class="mt-3 text-muted">Figure : Standard heat purification method for heat stable proteins. Full protocol can be found here (LINK). After the centrifugation step, the heat stable proteins can be found in the supernatant of the solution. The others, which
| + | <figcaption class="mt-3 text-muted">Gel electrophoresis of both the HexaHistidine insert (first gel) and the Encapsulin and plasmid backbone (second gel) . The bands at the correct length were extracted and assembled using a Golden Gate assembly. |
− | have been denatured, aggregate and are found in the pellet.
| + | </figcaption> |
− | </figcaption>
| + | |
− | </figure>
| + | |
− | <br>
| + | |
| | | |
− | <p class="lead">Right after the end of the expression, we performed standard heat purification. Our protein of interest, HexaHistidine Encapsulin is extremely heat stable and should be found in the supernatant of the sample after heat purification.
| + | </figure> |
− | </p>
| + | |
| | | |
− | <br>
| + | <br> |
| | | |
− | <p class="lead">We observed the cell-free expression products before and after heat purification thanks to SDS-PAGE and coomassie staining. The full protocol can be found here (LINK).
| + | <figure> |
− | </p>
| + | <img src="https://static.igem.org/mediawiki/2018/e/ec/T--EPFL--vaccine_result4.png" class="img-center img-fluid rounded shadow" width="400"> |
− | <br>
| + | </figure> |
| | | |
| + | <br> |
| | | |
| + | <h1 id="HHE">HexaHistidine Encapsulin cell-free expression and purification</h1> |
| + | <br> |
| | | |
− | </div>
| + | <p class="lead">In this section, we show some results of our trials to express HexaHistidine Encapsulin in our cell-free systems, as well as heat purify it.</p> |
| | | |
− | <div class="row row-grid align-items-center">
| + | <p class="lead">The cell-free expression were done following a standard protocol (LINK): 8 to 12h of expression at 29°C with shaking (600rpm).</p> |
− | <div class="col-lg-3">
| + | |
| | | |
| + | <br> |
| | | |
| <figure> | | <figure> |
− | <img src="https://static.igem.org/mediawiki/2018/d/dc/T--EPFL--vaccine_result6.png" class="img-center img-fluid rounded shadow" width="800"> | + | <img src="https://static.igem.org/mediawiki/2018/3/3f/T--EPFL--vaccine_result5.png" class="img-center img-fluid rounded shadow" width="800"> |
− | <figcaption class="mt-3 text-muted">Figure 3: SDS-PAGE gel after coomassie staining. B: before heat purification S: supernatant of the sample after heat purification | + | <figcaption class="mt-3 text-muted">Figure : Standard heat purification method for heat stable proteins. Full protocol can be found here (LINK). After the centrifugation step, the heat stable proteins can be found in the supernatant of the solution. The others, which |
| + | have been denatured, aggregate and are found in the pellet. |
| </figcaption> | | </figcaption> |
| </figure> | | </figure> |
| + | <br> |
| | | |
− | </div>
| + | <p class="lead">Right after the end of the expression, we performed standard heat purification. Our protein of interest, HexaHistidine Encapsulin is extremely heat stable and should be found in the supernatant of the sample after heat purification. |
| + | </p> |
| | | |
| + | <br> |
| | | |
− | <div class="col-lg-9">
| + | <p class="lead">We observed the cell-free expression products before and after heat purification thanks to SDS-PAGE and coomassie staining. The full protocol can be found here (LINK). |
− | <p class="lead">Before heat purification, in the sample expressed with HexaHistidine Encapsulin DNA template, we can distinguish a band at around 31 kDa among many other proteins. This band being absent in the negative control lane, might be Encapsulin | + | |
− | monomers. We also see a band at higher molecular weight, also not present in the negative control sample, which might be Encapsulin multimers.
| + | |
| </p> | | </p> |
| + | <br> |
| | | |
− | <p class="lead">After heat purification, we see a distinct band at around 31 kDa which is not present in the negative control. We can therefore hypothesize that this are Encapsulin monomers. All the other proteins that surrounded it before heat purification
| |
− | are not here anymore. This show that the Encapsulin has not been denatured during the process of heat purification, unlike the other ones. On top of that, we also still see the higher molecular weight band. This purification method
| |
− | is therefore suitable to HexaHistidine Encapsulin and allow us to get rid of the majority of the non desired proteins, as it can be seen on the gel.
| |
− | </p>
| |
| | | |
− | <br>
| |
| | | |
− | <p class="lead">The high molecular weight band on our SDS-PAGE gels gives good hints that the Encapsulin properly assembles in its spherical form. However, we performed DLS measurements to assess if fully assembled 60-mers nanoparticles occurred.
| |
− | </p>
| |
| </div> | | </div> |
| | | |
| + | <div class="row row-grid align-items-center"> |
| + | <div class="col-lg-3"> |
| | | |
− | </div>
| |
| | | |
| + | <figure> |
| + | <img src="https://static.igem.org/mediawiki/2018/d/dc/T--EPFL--vaccine_result6.png" class="img-center img-fluid rounded shadow" width="800"> |
| + | <figcaption class="mt-3 text-muted">Figure 3: SDS-PAGE gel after coomassie staining. B: before heat purification S: supernatant of the sample after heat purification |
| + | </figcaption> |
| + | </figure> |
| | | |
| + | </div> |
| | | |
| | | |
| + | <div class="col-lg-9"> |
| + | <p class="lead">Before heat purification, in the sample expressed with HexaHistidine Encapsulin DNA template, we can distinguish a band at around 31 kDa among many other proteins. This band being absent in the negative control lane, might be Encapsulin |
| + | monomers. We also see a band at higher molecular weight, also not present in the negative control sample, which might be Encapsulin multimers. |
| + | </p> |
| | | |
− | <figure>
| + | <p class="lead">After heat purification, we see a distinct band at around 31 kDa which is not present in the negative control. We can therefore hypothesize that this are Encapsulin monomers. All the other proteins that surrounded it before heat purification |
− | <img src="https://static.igem.org/mediawiki/2018/6/63/T--EPFL--vaccine_result8.png" class="img-center img-fluid rounded shadow" width="800">
| + | are not here anymore. This show that the Encapsulin has not been denatured during the process of heat purification, unlike the other ones. On top of that, we also still see the higher molecular weight band. This purification method |
− | <figcaption class="mt-3 text-muted">Figure : Negative control, TX-TL cell free expression medium purified according to the same procedure described above. The refractive index chosen for the particles was the "protein" presetting and the refractive index of the medium
| + | is therefore suitable to HexaHistidine Encapsulin and allow us to get rid of the majority of the non desired proteins, as it can be seen on the gel. |
− | was approximated to be that of water.
| + | </p> |
| | | |
− | </figcaption>
| + | <br> |
− | </figure>
| + | |
| | | |
− | <br>
| + | <p class="lead">The high molecular weight band on our SDS-PAGE gels gives good hints that the Encapsulin properly assembles in its spherical form. However, we performed DLS measurements to assess if fully assembled 60-mers nanoparticles occurred. |
| + | </p> |
| + | </div> |
| | | |
− | <div class="row row-grid align-items-center">
| |
− | <div class="col-lg-3">
| |
| | | |
| + | </div> |
| | | |
− | <figure>
| |
− | <img src="https://static.igem.org/mediawiki/2018/d/dc/T--EPFL--vaccine_result6.png" class="img-center img-fluid rounded shadow" width="800">
| |
| | | |
− | </figure>
| |
| | | |
− | </div>
| |
| | | |
| | | |
− | <div class="col-lg-9"> | + | <figure> |
− | <p class="lead text-muted">Figure : DLS measurement of Encapsulin <a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K2686002"><span style="color:blue">BBa_K2686002</span></a> using a Zetasizer Nano ZS from Malvern Analytical determining the average | + | <img src="https://static.igem.org/mediawiki/2018/6/63/T--EPFL--vaccine_result8.png" class="img-center img-fluid rounded shadow" width="800"> |
− | particle size using volumes. The refractive index chosen for the particles was the "protein" presetting and the refractive index of the medium was approximated to be that of water. This plot shows a peak at 21.037nm which corresponds
| + | <figcaption class="mt-3 text-muted">Figure : Negative control, TX-TL cell free expression medium purified according to the same procedure described above. The refractive index chosen for the particles was the "protein" presetting and the refractive index of the medium |
− | to the encapsulin protein cage within the literature (Putri et al., 2017; Moon et al. 2014).
| + | was approximated to be that of water. |
− | </p>
| + | |
− | </div>
| + | |
| | | |
| + | </figcaption> |
| + | </figure> |
| | | |
− | </div>
| + | <br> |
| + | <figure> |
| + | <img src="https://static.igem.org/mediawiki/2018/f/f4/T--EPFL--vacc_1.png" class="img-center img-fluid rounded shadow" width="800"> |
| + | </figure> |
| | | |
| + | <br> |
| | | |
| + | <figure> |
| + | <img src="https://static.igem.org/mediawiki/2018/8/8b/T--EPFL--vacc_2.png" class="img-center img-fluid rounded shadow" width="800"> |
| + | </figure> |
| | | |
− | <br>
| + | <br> |
| | | |
− | <h1 id="PlasmidContrsuction2">Plasmid construction (HexaHistidine Encapsulin with C-terminus BsaI cut sites)</h1>
| + | <figure> |
| + | <img src="https://static.igem.org/mediawiki/2018/0/09/T--EPFL--vaccine_result7.png" class="img-center img-fluid rounded shadow" width="800"> |
| + | </figure> |
| | | |
− | <p class="lead">The sfGFP coding insert was amplified and gel extracted (left), and the encapsulin containing plasmids had their backbones linearized through PCR (right).</p>
| + | <br> |
| | | |
− | <br>
| + | <figure> |
− | <div class="row row-grid align-items-center">
| + | <img src="https://static.igem.org/mediawiki/2018/7/70/T--EPFL--vacc_5.png" class="img-center img-fluid rounded shadow" width="800"> |
− | <div class="col-lg-6 ml-lg-auto"> | + | <figcaption class="mt-3 text-muted">Figure : DLS measurements of Encapsulin <a href="http://parts.igem.org/Part:BBa_K2686002#Dendritic_Cell_Uptake">K2686002</a> using a Zetasizer Nano ZS from Malvern Analytical determining the average particle size using volumes, intensities |
− | <figure> | + | and counts. The refractive index chosen for the particles was the "protein" presetting and the refractive index of the medium was approximated to be that of water. These plots shows a peak at 21.037nm,18.166nm and 32.674nm which corresponds |
− | <img src="https://static.igem.org/mediawiki/2018/1/10/T--EPFL--vaccine_result9.png" class="img-center img-fluid rounded shadow">
| + | to the encapsulin protein cage within the literature (Putri et al., 2017; Moon et al. 2014) when taking into account the peculiarities of each measurement method, since Intensity is highly sensitive to small amount of larger aggregates |
− | </div>
| + | (these could be some small aggregated proteins, explaining the larger size of the peak). The counts and volume based methods require the refractive indices and absorbance coefficients to be known (these were merely approximated) creating |
| + | a source of error ((Stetefeld, McKenna and Patel, 2016)(Zetasizer user manual)). |
| | | |
− | <div class="col-lg-6 ml-lg-auto"> | + | </figcaption> |
| + | </figure> |
| | | |
− | <figure>
| + | <br> |
− | <img src="https://static.igem.org/mediawiki/2018/8/86/T--EPFL--vaccine_result10.png" class="img-center img-fluid rounded shadow">
| + | |
− | </figure>
| + | |
| | | |
| + | <figure> |
| + | <img src="https://static.igem.org/mediawiki/2018/9/97/T--EPFL--vacc_3.24.png" class="img-center img-fluid rounded shadow" width="800"> |
| + | </figure> |
| + | <br> |
| + | <figure> |
| + | <img src="https://static.igem.org/mediawiki/2018/c/c3/T--EPFL--vacc_3.18.png" class="img-center img-fluid rounded shadow" width="800"> |
| + | </figure> |
| + | |
| + | <br> |
| + | |
| + | <figure> |
| + | <img src="https://static.igem.org/mediawiki/2018/5/59/T--EPFL--vacc_3.9.png" class="img-center img-fluid rounded shadow" width="800"> |
| + | <figcaption class="mt-3 text-muted">Figure: DLS measurements of part |
| + | <a href="http://parts.igem.org/Part:BBa_K2686000#Dendritic_Cell_Uptake">K2686000</a> where the results are highly inconclusive. The DLS measurements using the same techniques do not overlap at all, which indicates either an experimental |
| + | error or a mistake with the handling of the cell-free expression. Because of that no conclusions can be drawn from these measurements. |
| + | |
| + | </figcaption> |
| + | </figure> |
| + | |
| + | |
| + | |
| + | |
| + | |
| + | |
| + | |
| + | |
| + | |
| + | <br> |
| + | |
| + | <h1 id="PlasmidContrsuction2">Plasmid construction (HexaHistidine Encapsulin with C-terminus BsaI cut sites)</h1> |
| + | |
| + | <p class="lead">The sfGFP coding insert was amplified and gel extracted (left), and the encapsulin containing plasmids had their backbones linearized through PCR (right).</p> |
| + | |
| + | <br> |
| + | <div class="row row-grid align-items-center"> |
| + | <div class="col-lg-6 ml-lg-auto"> |
| + | <figure> |
| + | <img src="https://static.igem.org/mediawiki/2018/1/10/T--EPFL--vaccine_result9.png" class="img-center img-fluid rounded shadow"> |
| + | </div> |
| + | |
| + | <div class="col-lg-6 ml-lg-auto"> |
| + | |
| + | <figure> |
| + | <img src="https://static.igem.org/mediawiki/2018/8/86/T--EPFL--vaccine_result10.png" class="img-center img-fluid rounded shadow"> |
| + | </figure> |
| + | |
| + | </div> |
| </div> | | </div> |
− | </div>
| |
| | | |
− | <br>
| + | <br> |
| | | |
− | <p class="lead">The bands were then gel extracted and a Golden Gate assembly using the Esp3I type IIs restriction enzyme was used to build the construct with BsaI cut sites.
| + | <p class="lead">The bands were then gel extracted and a Golden Gate assembly using the Esp3I type IIs restriction enzyme was used to build the construct with BsaI cut sites. |
− | </p>
| + | </p> |
− | <br>
| + | <br> |
| | | |
| | | |
− | <figure>
| + | <figure> |
− | <img src="https://static.igem.org/mediawiki/2018/5/58/T--EPFL--vaccine_result11.png" class="img-center img-fluid rounded shadow" width="400">
| + | <img src="https://static.igem.org/mediawiki/2018/5/58/T--EPFL--vaccine_result11.png" class="img-center img-fluid rounded shadow" width="400"> |
− | </figure>
| + | </figure> |
| | | |
− | <br>
| + | <br> |
| | | |
− | <h1>Incorporation of the OT1 coding sequence into our platform</h1>
| + | <h1>Incorporation of the OT1 coding sequence into our platform</h1> |
| | | |
− | <p class="lead">We then wished to test our platform by inserting a peptide sequence in the C-terminus cutsite. We chose to insert the coding sequence of the peptide OT-1, a well-characterized epitope of the protein OVA (Ovalbumin). Indeed, the last step
| + | <p class="lead">We then wished to test our platform by inserting a peptide sequence in the C-terminus cutsite. We chose to insert the coding sequence of the peptide OT-1, a well-characterized epitope of the protein OVA (Ovalbumin). Indeed, the last step |
− | of our vaccine characterization would be to perform dendritic cell assay in order to assess the vaccine’s immunogenicity. One of the assay is to check if the right peptide is presented on MHC I molecules by the dendritic cells. This
| + | of our vaccine characterization would be to perform dendritic cell assay in order to assess the vaccine’s immunogenicity. One of the assay is to check if the right peptide is presented on MHC I molecules by the dendritic cells. This |
− | requires antibody targeting the peptide/MHC I molecule complex. Such antibodies are commercially available for OT1.
| + | requires antibody targeting the peptide/MHC I molecule complex. Such antibodies are commercially available for OT1. |
− | </p>
| + | </p> |
| | | |
− | <br>
| + | <br> |
| | | |
− | <figure>
| + | <figure> |
− | <img src="https://static.igem.org/mediawiki/2018/c/cf/T--EPFL--vaccine_result12.png" class="img-center img-fluid rounded shadow" width="400">
| + | <img src="https://static.igem.org/mediawiki/2018/c/cf/T--EPFL--vaccine_result12.png" class="img-center img-fluid rounded shadow" width="400"> |
− | </figure>
| + | </figure> |
| | | |
− | <br>
| + | <br> |
| | | |
− | <h1 id="EncapOT1">Encapsulin-OT1 cell-free expression and purification </h1>
| + | <h1 id="EncapOT1">Encapsulin-OT1 cell-free expression and purification </h1> |
| | | |
− | <figure>
| + | <figure> |
− | <img src="https://static.igem.org/mediawiki/2018/1/1d/T--EPFL--vaccine_result13.png" class="img-center img-fluid rounded shadow" width="300">
| + | <img src="https://static.igem.org/mediawiki/2018/1/1d/T--EPFL--vaccine_result13.png" class="img-center img-fluid rounded shadow" width="300"> |
− | <figcaption class="mt-3 text-muted">Figure 3: SDS-PAGE gel after coomassie staining. B: before heat purification S: supernatant of the sample after heat purification
| + | <figcaption class="mt-3 text-muted">Figure 3: SDS-PAGE gel after coomassie staining. B: before heat purification S: supernatant of the sample after heat purification |
− | </figure>
| + | </figure> |
| | | |
− | <br>
| + | <br> |
| | | |
− | <p class="lead">Before and after purification, we see a high molecular weight band in the HexaHistidine Encapsulin-OT1 lanes that are similar to the ones in the non-modified HexaHistidine Encapsulin lanes. This is a good indication of expression and proper
| + | <p class="lead">Before and after purification, we see a high molecular weight band in the HexaHistidine Encapsulin-OT1 lanes that are similar to the ones in the non-modified HexaHistidine Encapsulin lanes. This is a good indication of expression and proper |
− | assembly of our product.</p>
| + | assembly of our product.</p> |
| | | |
| | | |
− | <br>
| + | <br> |
| | | |
− | <h1 id="massSpec">Encapsulin-OT1 mass spec</h1>
| + | <h1 id="massSpec">Encapsulin-OT1 mass spec</h1> |
| | | |
− | <figure>
| + | <figure> |
− | <img src="https://static.igem.org/mediawiki/2018/3/3c/T--EPFL--vaccine_result14.png" class="img-center img-fluid rounded shadow" width="800">
| + | <img src="https://static.igem.org/mediawiki/2018/3/3c/T--EPFL--vaccine_result14.png" class="img-center img-fluid rounded shadow" width="800"> |
− | <figcaption class="mt-3 text-muted">The gel was stained with Coomassie blue and then given to the Proteomics Core Facility, where the two bands shown surrounded by squares were excised.
| + | <figcaption class="mt-3 text-muted">The gel was stained with Coomassie blue and then given to the Proteomics Core Facility, where the two bands shown surrounded by squares were excised. |
| | | |
− | </figure>
| + | </figure> |
| | | |
− | <br>
| + | <br> |
− | <p class="lead"><b>All manipulations after this step were <u>not</u> performed by us according to Protocol</b></p>
| + | <p class="lead"><b>All manipulations after this step were <u>not</u> performed by us according to Protocol</b></p> |
| | | |
− | <br>
| + | <br> |
| | | |
− | <p class="lead">The Proteomics Core Facility then washed the gel we provided, reduced and alkylated it, digested the proteins using trypsin and extracted the peptides to perform MALDI-TOF mass spec. The analysis of the results was also performed by the
| + | <p class="lead">The Proteomics Core Facility then washed the gel we provided, reduced and alkylated it, digested the proteins using trypsin and extracted the peptides to perform MALDI-TOF mass spec. The analysis of the results was also performed by the |
− | facility and we were provided the peptide sequence alignments onto the HexaHistidine Encapsulin-OT1 construct.
| + | facility and we were provided the peptide sequence alignments onto the HexaHistidine Encapsulin-OT1 construct. |
− | </p>
| + | </p> |
| | | |
− | <h1 id="HHEOT1">HexaHistidine Encapsulin-OT1</h1>
| + | <h1 id="HHEOT1">HexaHistidine Encapsulin-OT1</h1> |
| | | |
− | <br>
| + | <br> |
| | | |
− | <figure>
| + | <figure> |
− | <img src="https://static.igem.org/mediawiki/2018/3/31/T--EPFL--vaccine_result15.png" class="img-center img-fluid rounded shadow" width="800">
| + | <img src="https://static.igem.org/mediawiki/2018/3/31/T--EPFL--vaccine_result15.png" class="img-center img-fluid rounded shadow" width="800"> |
− | </figure>
| + | </figure> |
− | <br>
| + | <br> |
| | | |
− | <p class="lead">This image was taken in Scaffold Viewer 4, where the peptides identified from mass spec are aligned to the HexaHistidine Encapsulin-OT1 sequence using a peptide threshold of 1% FDR. The OT1 peptide has alignments with peptides at the encapsulin’s
| + | <p class="lead">This image was taken in Scaffold Viewer 4, where the peptides identified from mass spec are aligned to the HexaHistidine Encapsulin-OT1 sequence using a peptide threshold of 1% FDR. The OT1 peptide has alignments with peptides at the encapsulin’s |
− | C terminus which indicates that the OT1 peptide is successfully expressed.</p>
| + | C terminus which indicates that the OT1 peptide is successfully expressed.</p> |
| | | |
| | | |
| | | |
− | <br>
| + | <br> |
| | | |
− | <figure>
| + | <figure> |
− | <img src="https://static.igem.org/mediawiki/2018/6/6e/T--EPFL--vaccine_result16.png" class="img-center img-fluid rounded shadow" width="800">
| + | <img src="https://static.igem.org/mediawiki/2018/6/6e/T--EPFL--vaccine_result16.png" class="img-center img-fluid rounded shadow" width="800"> |
− | </figure>
| + | </figure> |
| | | |
− | <p>Spectrum of peptide FSIINFEKL at 1% FDR threshold</p>
| + | <p class="lead">Spectrum of peptide FSIINFEKL at 1% FDR threshold</p> |
| | | |
| | | |
− | <br>
| + | <br> |
| | | |
− | <figure>
| + | <figure> |
− | <img src="https://static.igem.org/mediawiki/2018/3/31/T--EPFL--vaccine_result15.png" class="img-center img-fluid rounded shadow" width="800">
| + | <img src="https://static.igem.org/mediawiki/2018/3/31/T--EPFL--vaccine_result15.png" class="img-center img-fluid rounded shadow" width="800"> |
− | </figure>
| + | </figure> |
| | | |
| | | |
− | <br>
| + | <br> |
| | | |
− | <p>Fragmentation table of FSIINFEK, cutoff at 95% probablilty</p>
| + | <p class="lead">Fragmentation table of FSIINFEK, cutoff at 95% probablilty</p> |
| | | |
| | | |
− | <br>
| + | <br> |
| | | |
− | <h1 id="HHEcontrol">HexaHistidine Encapsulin (control)</h1>
| + | <h1 id="HHEcontrol">HexaHistidine Encapsulin (control)</h1> |
| | | |
− | <figure>
| + | <figure> |
− | <img src="https://static.igem.org/mediawiki/2018/4/44/T--EPFL--vaccine_result18.png" class="img-center img-fluid rounded shadow" width="800">
| + | <img src="https://static.igem.org/mediawiki/2018/4/44/T--EPFL--vaccine_result18.png" class="img-center img-fluid rounded shadow" width="800"> |
− | </figure>
| + | </figure> |
| | | |
− | <br>
| + | <br> |
| | | |
| | | |
− | <figure>
| + | <figure> |
− | <img src="https://static.igem.org/mediawiki/2018/c/cd/T--EPFL--vaccine_result19.png" class="img-center img-fluid rounded shadow" width="800">
| + | <img src="https://static.igem.org/mediawiki/2018/c/cd/T--EPFL--vaccine_result19.png" class="img-center img-fluid rounded shadow" width="800"> |
− | </figure>
| + | </figure> |
− | <br>
| + | <br> |
| | | |
− | <p class="lead">Here the HexaHistidine Encapsulin sample’s peptides are aligned to the HexaHistidine Encapsulin-OT1 sequence at 1% FDR cutoff (first image) and at 95% probability cutoff (second image). There are no peptides aligning to the SIINFEKL part
| + | <p class="lead">Here the HexaHistidine Encapsulin sample’s peptides are aligned to the HexaHistidine Encapsulin-OT1 sequence at 1% FDR cutoff (first image) and at 95% probability cutoff (second image). There are no peptides aligning to the SIINFEKL part |
− | of the sequence, which is the expected result since our protein does not have the peptide.</p>
| + | of the sequence, which is the expected result since our protein does not have the peptide.</p> |
| | | |
| | | |
− | <br>
| + | <br> |
| | | |
− | <p>Overall the purity of the samples is relatively good, and the important parts of the sequence were clearly identifiable.</p>
| + | <p class="lead">Overall the purity of the samples is relatively good, and the important parts of the sequence were clearly identifiable.</p> |
| | | |
− | <br>
| + | <br> |
| | | |
− | <h1 id="Encapuptake">Encapsulin uptake by dendritic cells</h1>
| + | <h1 id="Encapuptake">Encapsulin uptake by dendritic cells</h1> |
| | | |
− |
| |
| | | |
− | </div>
| + | |
− | <!--End of Vaccine results-->
| + | </div> |
| + | <!--End of Vaccine results--> |
| | | |
| <div class="tab-pane fade " id="FollowUp" role="tabpanel" aria-labelledby="home-tab"> | | <div class="tab-pane fade " id="FollowUp" role="tabpanel" aria-labelledby="home-tab"> |
Line 1,479: |
Line 1,860: |
| | | |
| <div class="tab-pane fade" id="ctDNA" role="tabpanel" aria-labelledby="contact-tab"> | | <div class="tab-pane fade" id="ctDNA" role="tabpanel" aria-labelledby="contact-tab"> |
− |
| + | |
| <br> | | <br> |
| <div class="row justify-content-center lead"> | | <div class="row justify-content-center lead"> |
Line 1,514: |
Line 1,895: |
| </div> | | </div> |
| </a> | | </a> |
− |
| + | |
− |
| + | |
| | | |
| </div> | | </div> |
Line 1,528: |
Line 1,909: |
| <p class="lead"> More precisely, we wanted to show that we could apply this technology for the purposes of our project: for this part, this means detecting our targeted neoantigens sequences. We also wanted to bring this technology a step further by detecting these fragments directly in the blood plasma, without the need of any isolation step. </p> | | <p class="lead"> More precisely, we wanted to show that we could apply this technology for the purposes of our project: for this part, this means detecting our targeted neoantigens sequences. We also wanted to bring this technology a step further by detecting these fragments directly in the blood plasma, without the need of any isolation step. </p> |
| <br> | | <br> |
− |
| + | |
| </div> | | </div> |
| </div> | | </div> |
Line 1,549: |
Line 1,930: |
| <p class="lead">According to recent studies (<a href="#Li2018"><span style="color:blue">Li <i>et al.</i>, 2018</span></a>), the Cas12a/PCR system yielded high cleavage specificity when crRNA guide sequences of reduced length (16-17 bp) were used, and they could demonstrate that even a single mismatch between the gRNA/target sequence (activator) resulted in more than two folds decrease in fluorescent signal when FQ reporter molecules were present in the solution.</p> | | <p class="lead">According to recent studies (<a href="#Li2018"><span style="color:blue">Li <i>et al.</i>, 2018</span></a>), the Cas12a/PCR system yielded high cleavage specificity when crRNA guide sequences of reduced length (16-17 bp) were used, and they could demonstrate that even a single mismatch between the gRNA/target sequence (activator) resulted in more than two folds decrease in fluorescent signal when FQ reporter molecules were present in the solution.</p> |
| <p class="lead">Thus, we wanted to demonstrate that we can reproduce these results by first successfully amplifying our target sequences in plasma and use this afterwards as a DNA substrate for the Cas12a assay. In this set of experiments, we worked mainly with the second region (Figure 1), since it already contains the PAM sequence and we did not want to accumulate the sources of potential errors. Results of the amplification of 10 pM of either BRAF mutated fragment or the original one (region 2) is shown below.</p> | | <p class="lead">Thus, we wanted to demonstrate that we can reproduce these results by first successfully amplifying our target sequences in plasma and use this afterwards as a DNA substrate for the Cas12a assay. In this set of experiments, we worked mainly with the second region (Figure 1), since it already contains the PAM sequence and we did not want to accumulate the sources of potential errors. Results of the amplification of 10 pM of either BRAF mutated fragment or the original one (region 2) is shown below.</p> |
− |
| + | |
| <center> | | <center> |
| <figure> | | <figure> |
Line 1,568: |
Line 1,949: |
| <p class="lead">We can see that a point mutation inducing a mismatch between the guide RNA sequence (gRNA) and the target region resulted in more than 2-fold difference in fluorescent signal, which is coherent with our hypothesis suggesting the high cleavage specificity of the Cas12a/crRNA binary complex. </p> | | <p class="lead">We can see that a point mutation inducing a mismatch between the guide RNA sequence (gRNA) and the target region resulted in more than 2-fold difference in fluorescent signal, which is coherent with our hypothesis suggesting the high cleavage specificity of the Cas12a/crRNA binary complex. </p> |
| <p class="lead">Besides, it is relevant to notice that the Cas12a system was not activated by any noisy background (i.e. the different cell-free DNA fragments present naturally in the plasma other than the one we poured), which proves once again the high specificity of our system.</p> | | <p class="lead">Besides, it is relevant to notice that the Cas12a system was not activated by any noisy background (i.e. the different cell-free DNA fragments present naturally in the plasma other than the one we poured), which proves once again the high specificity of our system.</p> |
− |
| + | |
| <br> | | <br> |
| <br> | | <br> |
| <h4>Result 2: Characterisation of the sensitivity of the Cas12a/PCR system</h4> | | <h4>Result 2: Characterisation of the sensitivity of the Cas12a/PCR system</h4> |
| <p class="lead">Next, we wanted to investigate the correlation between the concentration of Cas12a target strand and the degree of activation of the protein (fluorescent signal), by lowering the concentration of DNA in our sample reaction mix, and testing the sensitivity of our system in the fM range. Amplification of the second region of respectively 10 pM and 10 fM initial concentration of BRAF mutated DNA template was performed.</p> | | <p class="lead">Next, we wanted to investigate the correlation between the concentration of Cas12a target strand and the degree of activation of the protein (fluorescent signal), by lowering the concentration of DNA in our sample reaction mix, and testing the sensitivity of our system in the fM range. Amplification of the second region of respectively 10 pM and 10 fM initial concentration of BRAF mutated DNA template was performed.</p> |
− |
| + | |
| <center> | | <center> |
| <figure> | | <figure> |
Line 1,585: |
Line 1,966: |
| <br> | | <br> |
| <p class="lead">The Cas12a detection assay was performed afterwards separately using the PCR reactions as DNA substrates (activators). Results are shown in the Figure 5.</p> | | <p class="lead">The Cas12a detection assay was performed afterwards separately using the PCR reactions as DNA substrates (activators). Results are shown in the Figure 5.</p> |
− |
| + | |
| <center> | | <center> |
| <figure> | | <figure> |
Line 1,595: |
Line 1,976: |
| <p class="lead">Again, the specificity of the RNA guiding DNA binding was demonstrated at different sensitivity levels.</p> | | <p class="lead">Again, the specificity of the RNA guiding DNA binding was demonstrated at different sensitivity levels.</p> |
| <p class="lead">The activation was excellent when our activator (10 pM before amplification) was targeted with the complementary crRNA guide sequence, with more than 4-folds difference in fluorescent signal when targeted with the point mutated one. 10 fM activator yielded a lower fluorescent signal when targeted with a complementary crRNA (and nearly no signal at all when a single point mismatch was present), which is in agreement with the hypothesis that a higher concentration of targeted DNA present in the reaction will significantly increase the Cas12a collateral endonuclease activity, resulting in an overall increase in fluorescence. This is indeed confirmed by the gel (Figure 2) that shows more efficient amplification for the 10 pM fragment.</p> | | <p class="lead">The activation was excellent when our activator (10 pM before amplification) was targeted with the complementary crRNA guide sequence, with more than 4-folds difference in fluorescent signal when targeted with the point mutated one. 10 fM activator yielded a lower fluorescent signal when targeted with a complementary crRNA (and nearly no signal at all when a single point mismatch was present), which is in agreement with the hypothesis that a higher concentration of targeted DNA present in the reaction will significantly increase the Cas12a collateral endonuclease activity, resulting in an overall increase in fluorescence. This is indeed confirmed by the gel (Figure 2) that shows more efficient amplification for the 10 pM fragment.</p> |
− |
| + | |
− |
| + | |
| <br> | | <br> |
| <br> | | <br> |
Line 1,619: |
Line 2,000: |
| <p class="lead">Again here we have a good correlation between the concentration of activator and the level of activation of Cas12a, (although the 100 fM signal is above the 1 fM). This also means that the addition of the PAM sequence through PCR amplification worked correctly.</p> | | <p class="lead">Again here we have a good correlation between the concentration of activator and the level of activation of Cas12a, (although the 100 fM signal is above the 1 fM). This also means that the addition of the PAM sequence through PCR amplification worked correctly.</p> |
| <p class="lead">Finally, these results allow us to say that 1 fM of target DNA is the minimum detectable concentration for the Cas12a/PCR-from-plasma system in this experiment, since we couldn’t detect any signal in the attomolar range. </p> | | <p class="lead">Finally, these results allow us to say that 1 fM of target DNA is the minimum detectable concentration for the Cas12a/PCR-from-plasma system in this experiment, since we couldn’t detect any signal in the attomolar range. </p> |
− |
| + | |
− |
| + | |
| <br> | | <br> |
| <br> | | <br> |
Line 1,635: |
Line 2,016: |
| <br> | | <br> |
| <p class="lead">Agarose gel electrophoresis gel after amplification is shown below.</p> | | <p class="lead">Agarose gel electrophoresis gel after amplification is shown below.</p> |
− |
| + | |
| <center> | | <center> |
| <figure> | | <figure> |
Line 1,644: |
Line 2,025: |
| <br> | | <br> |
| <p class="lead">One interesting thing to say about this result is that there is no way of discriminating SNP between two fragments when these are put together in the same sample. This was however possible to do with the Cas12a assay (Figure 10).</p> | | <p class="lead">One interesting thing to say about this result is that there is no way of discriminating SNP between two fragments when these are put together in the same sample. This was however possible to do with the Cas12a assay (Figure 10).</p> |
− |
| + | |
| <center> | | <center> |
| <figure> | | <figure> |
Line 1,719: |
Line 2,100: |
| <br> | | <br> |
| <p class="lead">If you would like to see our experiments in more details, please look at our <a href="2018.igem.org/Team:EPFL/Notebook-Detection-ctDNA"><span style="color:blue">Notebooks</span></a>.</p> | | <p class="lead">If you would like to see our experiments in more details, please look at our <a href="2018.igem.org/Team:EPFL/Notebook-Detection-ctDNA"><span style="color:blue">Notebooks</span></a>.</p> |
− |
| + | |
| <br> | | <br> |
| <hr style="height:2px;border:none;color:#333;background-color:#333;" /> | | <hr style="height:2px;border:none;color:#333;background-color:#333;" /> |
Line 1,735: |
Line 2,116: |
| </ul> | | </ul> |
| </div> | | </div> |
− |
| + | |
| <div class="col-lg-6"> | | <div class="col-lg-6"> |
| <h2>What presented issues</h2> | | <h2>What presented issues</h2> |
Line 1,745: |
Line 2,126: |
| </div> | | </div> |
| </div> | | </div> |
− |
| + | |
| <br> | | <br> |
| <hr style="height:2px;border:none;color:#333;background-color:#333;" /> | | <hr style="height:2px;border:none;color:#333;background-color:#333;" /> |
− |
| + | |
− |
| + | |
| <article> | | <article> |
| <h2><i><u>References</u></i></h2> | | <h2><i><u>References</u></i></h2> |
Line 1,757: |
Line 2,138: |
| <li id="deKlein1982">de Klein, Annelies, et al. "A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia." <i>Nature</i>, 300.5894 (1982): 765.</li> | | <li id="deKlein1982">de Klein, Annelies, et al. "A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia." <i>Nature</i>, 300.5894 (1982): 765.</li> |
| <li id="Li2018">Li, Shi-Yuan, et al. "CRISPR-Cas12a-assisted nucleic acid detection." <i>Cell discovery</i>, 4.1 (2018): 20.</li> | | <li id="Li2018">Li, Shi-Yuan, et al. "CRISPR-Cas12a-assisted nucleic acid detection." <i>Cell discovery</i>, 4.1 (2018): 20.</li> |
− |
| + | |
| </ul> | | </ul> |
| </article> | | </article> |
− |
| |
| | | |
− |
| + | |
| + | |
| </div> | | </div> |
| | | |